IBU-TAB 200
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IBU-TAB 200 (IBU-TAB 200).
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism primarily via CYP2C9. |
| Excretion | Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%. |
| Half-life | 2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect. |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.1-0.2 L/kg (low Vd, confined to plasma and interstitial fluid). |
| Bioavailability | Oral: 80-100% (with food may reduce rate). |
| Onset of Action | Oral: 30-60 minutes (analgesic); rectal: 60-90 minutes. |
| Duration of Action | Oral: 4-6 hours (analgesic), 6-8 hours (antipyretic). Rectal: similar but variable. |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: reduce dose by 50% or increase interval to every 8-12 hours; eGFR <30 mL/min: avoid use or maximum 400 mg/day. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | 6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day. For fever or pain: 5 mg/kg per dose for temperatures <102.5°F, 10 mg/kg per dose for higher fever. |
| Geriatric use | Start at lowest effective dose (200 mg every 6-8 hours); maximum 400 mg/day due to increased risk of renal and GI adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IBU-TAB 200 (IBU-TAB 200).
| Breastfeeding | Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. Monitor infant for rash, gastrointestinal effects, or drowsiness. |
| Teratogenic Risk | First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; no clear teratogenic risk but may cause premature closure of ductus arteriosus. Third trimester: Contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk.
| Serious Effects |
Hypersensitivity to ibuprofen or NSAIDs, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of coronary artery bypass graft (CABG) surgery, severe renal impairment, active peptic ulcer disease.
| Precautions | Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, anaphylactoid reactions, hepatic effects, asthma exacerbation, pregnancy avoidance (third trimester). |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of gastrointestinal bleeding. Fetal monitoring includes ultrasound for amniotic fluid index and ductus arteriosus patency if used in third trimester. |
| Fertility Effects | Reversible impairment of female fertility via inhibition of prostaglandin synthesis affecting ovulation. May also affect male fertility through a negative impact on semen quality; effects are reversible upon discontinuation. |